Noile-Immune Biotech Inc. Statistics
Want to see JP:4893 full AI Analyst Report?
Noile-Immune Biotech Inc. (4893) Stock Statistics & Valuation Metrics
Total Valuation
Noile-Immune Biotech Inc. has a market cap or net worth of JPY 3.43B. The enterprise value is JPY 1.70B.
- Market Cap
- JPY 3.43B
- Enterprise Value
- JPY 1.70B
Share Statistics
Noile-Immune Biotech Inc. has 43,399,117 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 43,399,117
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
Noile-Immune Biotech Inc.’s return on equity (ROE) is -0.20 and return on invested capital (ROIC) is -20.25%.
- Return on Equity (ROE)
- -0.20
- Return on Assets (ROA)
- -0.20
- Return on Invested Capital (ROIC)
- -20.25%
- Return on Capital Employed (ROCE)
- -0.20
- Revenue Per Employee
- 217.39K
- Profits Per Employee
- -34.50M
- Employee Count
- 23
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Noile-Immune Biotech Inc. is -4.89. Noile-Immune Biotech Inc.’s PEG ratio is 0.44.
- PE Ratio
- -4.89
- PS Ratio
- 5159.32
- PB Ratio
- 1.03
- Price to FCF
- 0.00
- Price to Operating Cash Flow
- 0.00
- PEG Ratio
- 0.44
Income Statement
In the last 12 months, Noile-Immune Biotech Inc. had revenue of 5.00M and earned -793.54M in profits. Earnings per share was -18.33.
- Revenue
- 5.00M
- Gross Profit
- 5.00M
- Operating Income
- -797.25M
- Pretax Income
- -791.12M
- Net Income
- -793.54M
- EBITDA
- -797.25M
- Earnings Per Share (EPS)
- -18.33
Cash Flow
In the last 12 months, operating cash flow was 0 and capital expenditures 0, giving a free cash flow of 0 billion.
- Operating Cash Flow
- 0
- Free Cash Flow
- 0
- Free Cash Flow per Share
- 0.00
Dividends & Yields
Noile-Immune Biotech Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 0.00%
- Earnings Yield
- -20.22%
Stock Price Statistics
- Beta
- 0.81
- 52-Week Price Change
- -42.67%
- 50-Day Moving Average
- 114.14
- 200-Day Moving Average
- 136.21
- Relative Strength Index (RSI)
- 18.03
- Average Volume (3m)
- 206.57K
Important Dates
Noile-Immune Biotech Inc. upcoming earnings date is Nov 13, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 13, 2026
- Next Earnings Date
- Nov 13, 2026
- Ex-Dividend Date
- ―
Financial Position
Noile-Immune Biotech Inc. as a current ratio of 53.54, with Debt / Equity ratio of 0.00%
- Current Ratio
- 53.54
- Quick Ratio
- 53.51
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 4.91
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Noile-Immune Biotech Inc. has paid 2.42M in taxes.
- Income Tax
- 2.42M
- Effective Tax Rate
- -0.00
Enterprise Valuation
Noile-Immune Biotech Inc. EV to EBITDA ratio is -0.23, with an EV/FCF ratio of 0.00.
- EV to Sales
- 262.03
- EV to EBITDA
- -0.23
- EV to Free Cash Flow
- 0.00
- EV to Operating Cash Flow
- 0.00
Balance Sheet
Noile-Immune Biotech Inc. has JPY 3.54B in cash and marketable securities with JPY 0.00 in debt, giving a net cash position of JPY 3.54B billion.
- Cash & Marketable Securities
- JPY 3.54B
- Total Debt
- JPY 0.00
- Net Cash
- JPY 3.54B
- Net Cash Per Share
- JPY 81.68
- Tangible Book Value Per Share
- JPY 82.47
Margins
Gross margin is 0.00%, with operating margin of -112546.85%, and net profit margin of -105437.76%.
- Gross Margin
- 0.00%
- Operating Margin
- -112546.85%
- Pretax Margin
- -105149.65%
- Net Profit Margin
- -105437.76%
- EBITDA Margin
- -111989.79%
- EBIT Margin
- -111989.79%
Analyst Forecast
The average price target for Noile-Immune Biotech Inc. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -92.30%
- EPS Growth Forecast
- -8.80%
Scores
- Smart Score
- ―
- AI Score
- 42
